Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Filvaroff

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Science Translational Medicine|December 17, 2011
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1Ai-Luen Wu, Ganesh Kolumam, Scott Stawicki, et al.
Neuro-Oncology Advances|November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastomaMaria Vieito, Matteo Simonelli, Filip de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Science Translational Medicine|December 17, 2011
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1Ai-Luen Wu, Ganesh Kolumam, Scott Stawicki, et al.
Neuro-Oncology Advances|November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastomaMaria Vieito, Matteo Simonelli, Filip de Vos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Pageof 2